| Literature DB >> 31717277 |
Abstract
Propolis is a honey-related product with reported health benefits such as improved immunity, lowered blood pressure, treated allergies and skin conditions. A literature review and narrative synthesis were conducted to investigate the evidence on the reported health benefits and future direction of propolis products. Using a predefined search strategy we searched Medline (OvidSP), Embase and Central for quantitative and qualitative studies (1990-2018). Citation, reference, hand searches and expert consultation were also undertaken. Studies of randomised control trials and observational data on humans with health-related outcomes were included. Collected data were entered into NVivo software (Version 12, QRS International) and analysed using a thematic framework and a narrative synthesis of emergent themes. A total of 63 publications were discussed. The majority were cell-based and animal studies, with a few key human trials conducted. There is significant promise for propolis as an effective antioxidant and anti-inflammatory agent with particular promise in cardiometabolic health.Entities:
Keywords: bioactives; cardiovascular; nutrition; stroke
Mesh:
Substances:
Year: 2019 PMID: 31717277 PMCID: PMC6893770 DOI: 10.3390/nu11112705
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Summary of included studies derived for each theme.
| References | Theme Citation Count | Emergent Themes and Key Outcome Measures |
|---|---|---|
| [ | 34 | Anti-Cancer and Anti-Tumor Effects. Outcomes: Cancer cell culture response to propolis (apoptosis, regulatory markers, cancer cell formation, angiogenesis); apoptosis in brain cancer cell lines by propolin G (propolis component); apoptosis and caspase-3 in ischemic rats given pinocembrin; caspase 3 and cytochrome C in ischemic rats |
| [ | 53 | Anti-Inflammatory Activity. Outcomes: cell line inflammatory response to propolis constituents; oxidative stress in rat cortical neurons; IL-6 and TNF-α in rats with fatty liver disease given propolis; inflammation in injured human brain cells; TNF-α and NFkb in diabetic mice; inflammation in diabetic humans |
| [ | 33 | Antimicrobial and Antiviral Effect. Outcomes: Bacterial growth in propolis agar; parasite infected rats administered propolis; bacterial plaque and pathogenic microflora in the human mouth |
| [ | 35 | Cardioprotective Activity and Atherosclerosis. Outcomes: Atherosclerotic legions in propolis treated mice; total cholesterol, HDL, ALT and ALP in rats with fatty liver disease given propolis; infarct volume in ischemic rats given pinocembrin; mitochondrial function in mice given pinocembrin |
| [ | 51 | Characterising Propolis: Outcomes: Propolis compound identification; constituents of propolis-pinocembrin, propolin G; geographical location and source; flavonoid interactions |
| [ | 22 | Digestion and Metabolism. Outcomes: Bioavailability; taste, sensory and bioactivity of propolis in humans |
| [ | 27 | Dose and Safety. Outcomes: Tolerability of pinocembrin in humans; propolis induced no toxicity as determined by the ALT, AST and CK plasma levels in parasitic mice; edema, side effects, topical application; generally non-toxic in mice |
| [ | 151 | Free Radicals and Oxidative Stress. Outcomes: MDA, lipid peroxidation and antioxidant enzymes in homogenized brain tissue of irradiated rats and cerebral-injured mice; superoxide production, glutathione depletion and intracellular superoxide burst following propolis intake in humans; mitochondrial response of neuroblastoma cells to propolis treatment; neurotoxicity, apoptosis and oxidative stress in cultured retinal ganglion cells; nrf-2, ARE, HO-1 and γ-GCS expression in neuroblastoma cells treated with pinocembrin; MDA and PC in rats given propolis; nNOS, iNOS and glutathione in ischemic rats given pinocembrin; oxidative stress in liver and brain, DNA fragmentation in hepatic encephalopathy induced rats given propolis; brain SOD, CAT, GSH and MDA in brain damaged rats; myeloperoxidase, TNF-α, NF-kB, IL-6 and IL-10 in ischemic rats |
| [ | 8 | Gut Health. Outcomes: Human faecal in vitro fermentations of rutin; gut bacterial cell viability and production of SCFAs after propolis administration; parasite infected mice administered propolis |
| [ | 36 | Immune System Effects. Outcomes: mononuclear cell response to exercise following caffeic-acid phenethyl-ester ingestion; liver, kidney and immune cell response to propolis; splenic NK cytotoxic, T lymphocyte proliferation and antibody generation cells, as well as the phagocytosis of peritoneal macrophages, ear swelling and serum contents of IgG; IgM in mice within propolis vs. control |
| [ | 204 | Neuroprotection. Outcomes: Antioxidant enzymes, lipid peroxidation and infarct volume were measured post stroke in mice; toxicity in PC12 cells; behavioural performance of Dgal-treated mice; Cell viability and apoptosis in neuronal cells pretreated with pinocembrin and glutamate; Blood-brain barrier disruption was measured in rats with cerebral ischemia; cognitive test performance in rats given propolis; cell viability loss, apoptotic rate and decreased Bcl-2/Bax ratio in neuroblastoma cells; expression level of neurotrophic factors in dental pulp cells; oxidative stress in human neuroblastoma cells; induced seizures in rats given propolis; neurological ability and cognition in ischemic rats given pinocembrin; iNOS expression in hepatic encephalopathy induced rats given propolis; brain damaged rats behavioural assessment; cerebral edema in rats |
| [ | 44 | Study Design. Outcomes: Propolis compound identification; animal vs. human intervention; intervention length in human trials typically 4 weeks.; animal models of disease; gene expression profile following propolis administration; phenolic compounds; blood brain barrier uptake of pinocembrin |
| [ | 8 | Wound Healing and Skin Protection. Outcomes: Propolis and its protective effects on hydrogen peroxide-induced changes in mouse fibroblast cells; antimicrobial, antioxidant and anti-inflammatory properties in humans |
Key: IL-6: interleukin-6; TNF-α: tumor necrosis factor-alpha; NF-kB: nuclear factor kappa-B; HDL: high-density lipoprotein; ALT: alanine aminotransferase; ALP: alanine phosphatase; CK: creatine kinase; MDA: malondialdehyde; nrf-2: nuclear factor erythroid 2-related factor 2; ARE: antioxidant response element; HO-1: hemeoxygenase-1; γ-GCS: gamma-glutamylcysteine synthetase; PC: protein carbonyl; nNOS: neuronal nitrite oxide synthase; iNOS: inducible nitric oxide synthase; CAT: catalase; GSH: glutathione; IL-10: interleukin-10; SCFAs: short-chain fatty-acids; NK: natural killer; IgG: immunoglobulin G; IgM: immunoglobulin M; Bax: apotosis regulator.